---
title: "Kuehn Law 鼓励 Amylyx Pharmaceuticals, Inc. 的投资者与律师事务所联系"
description: "纽约，2025 年 10 月 10 日（GLOBE NEWSWIRE）—— Kuehn Law, PLLC，一家股东诉讼律师事务所，正在调查 Amylyx Pharmaceuticals, Inc.（纳斯达克代码：AMLX）的某些高管和董事是否违反了对股东的信托责任"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/260665900.md"
published_at: "2025-10-10T15:36:58.000Z"
---

# Kuehn Law 鼓励 Amylyx Pharmaceuticals, Inc. 的投资者与律师事务所联系

> 纽约，2025 年 10 月 10 日（GLOBE NEWSWIRE）—— Kuehn Law, PLLC，一家股东诉讼律师事务所，正在调查 Amylyx Pharmaceuticals, Inc.（纳斯达克代码：AMLX）的某些高管和董事是否违反了对股东的信托责任

NEW YORK, Oct. 10, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) breached their fiduciary duties to shareholders.

### Related Stocks

- [AMLX.US - Amylyx Pharmaceuticals](https://longbridge.com/zh-CN/quote/AMLX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cibc World Market Inc. Invests $1.22 Million in QXO, Inc. $QXO | Cibc World Market Inc. has invested $1.22 million in QXO, Inc. by acquiring 64,153 shares during Q3, as reported in its  | [Link](https://longbridge.com/zh-CN/news/276106337.md) |
| Medexus Pharmaceuticals reports Q3 results | Medexus Pharmaceuticals reports Q3 results | [Link](https://longbridge.com/zh-CN/news/275670725.md) |
| Baader Bank Aktiengesellschaft Sells 54,069 Shares of Nasdaq, Inc. $NDAQ | Baader Bank Aktiengesellschaft reduced its stake in Nasdaq, Inc. by 86.5% in Q3, selling 54,069 shares, leaving it with  | [Link](https://longbridge.com/zh-CN/news/275735016.md) |
| Almonty Industries Inc. (NASDAQ:ALM) Given Consensus Rating of "Moderate Buy" by Brokerages | Almonty Industries Inc. (NASDAQ:ALM) has received a consensus rating of "Moderate Buy" from five brokerages. One analyst | [Link](https://longbridge.com/zh-CN/news/275928257.md) |
| Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ \| CTOR Stock News | Citius Pharmaceuticals, Inc. reported $3.9 million in revenue from the launch of LYMPHIR™ in December 2025, marking its  | [Link](https://longbridge.com/zh-CN/news/275904512.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。